FibroBiologics Statistics

Total Valuation

FibroBiologics has a market cap or net worth of $33.29 million. The enterprise value is $29.86 million.

Market Cap	33.29M
Enterprise Value	29.86M

Important Dates

The next estimated earnings date is Friday, May 23, 2025, after market close.

Earnings Date	May 23, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroBiologics has 38.26 million shares outstanding. The number of shares has increased by 16.45% in one year.

Current Share Class	38.26M
Shares Outstanding	38.26M
Shares Change (YoY)	+16.45%
Shares Change (QoQ)	+1.82%
Owned by Insiders (%)	20.04%
Owned by Institutions (%)	17.18%
Float	28.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	11.16
P/TBV Ratio	12.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.12, with a Debt / Equity ratio of 3.86.

Current Ratio	1.12
Quick Ratio	1.10
Debt / Equity	3.86
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-686.85

Financial Efficiency

Return on equity (ROE) is -559.73% and return on invested capital (ROIC) is -105.42%.

Return on Equity (ROE)	-559.73%
Return on Assets (ROA)	-60.75%
Return on Invested Capital (ROIC)	-105.42%
Return on Capital Employed (ROCE)	-369.37%
Revenue Per Employee	n/a
Profits Per Employee	-$858,538
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-90.64%
50-Day Moving Average	1.03
200-Day Moving Average	2.09
Relative Strength Index (RSI)	40.40
Average Volume (20 Days)	217,760

Short Selling Information

The latest short interest is 1.59 million, so 4.15% of the outstanding shares have been sold short.

Short Interest	1.59M
Short Previous Month	1.53M
Short % of Shares Out	4.15%
Short % of Float	5.59%
Short Ratio (days to cover)	6.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.74M
Pretax Income	-19.47M
Net Income	-11.16M
EBITDA	-13.58M
EBIT	-13.74M
Earnings Per Share (EPS)	-$0.34

Full Income Statement

Balance Sheet

The company has $13.99 million in cash and $10.55 million in debt, giving a net cash position of $3.43 million or $0.09 per share.

Cash & Cash Equivalents	13.99M
Total Debt	10.55M
Net Cash	3.43M
Net Cash Per Share	$0.09
Equity (Book Value)	2.74M
Book Value Per Share	0.08
Working Capital	1.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$11.90 million and capital expenditures -$184,000, giving a free cash flow of -$12.09 million.

Operating Cash Flow	-11.90M
Capital Expenditures	-184,000
Free Cash Flow	-12.09M
FCF Per Share	-$0.32

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.45%
Shareholder Yield	-16.45%
Earnings Yield	-33.53%
FCF Yield	-36.30%

Analyst Forecast

The average price target for FibroBiologics is $13.00, which is 1,394.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.00
Price Target Difference	1,394.25%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	11.55%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1